Neurology advanced rapidly today across diagnostics, neurodegeneration, AI-enabled drug discovery, and next-generation neurotechnology. In this edition of Synopulse’s NeuroPulse, we highlight new multimillion-dollar collaborations, breakthrough imaging clearances, Parkinson’s and Huntington’s advances, and early-stage platform data shaping the next wave of neuroscience innovation.
ASPN Issues New Peripheral Nerve Stimulation Guideline, Setting a Major Benchmark for Neuromodulation Care
The American Society of Pain and Neuroscience (ASPN) has released a comprehensive new clinical guideline formally establishing peripheral nerve stimulation (PNS) as an evidence-based, guideline-supported therapy for chronic pain management a milestone that carries significant implications for neurology, pain medicine, and payer policy. The document consolidates high-quality clinical evidence, including multiple RCTs and real-world datasets, and endorses minimally invasive, time-limited PNS systems such as the 60-day SPRINT platform as effective options for patients who fail conservative therapy or face limited alternatives.
Unlike prior fragmented recommendations, ASPN’s guideline standardizes evaluation criteria, patient selection, outcome expectations, and procedural best practices, creating new clarity for clinicians and health systems. The guidance also directly addresses access barriers by recognizing PNS as a scalable, durable intervention with functional and cost-of-care benefits positioning it for expanded reimbursement across commercial and government payers. For the neuromodulation field, this represents a rare, high-impact alignment of evidence, clinical adoption, and payer-readiness, marking one of the most consequential guideline shifts in interventional pain and peripheral neurotechnology in recent years.
Deals, Funding & Grants Accelerate Across Neuroscience
Valo Health announced a landmark $3B+ AI-powered Parkinson’s discovery collaboration with Merck KGaA, leveraging Valo’s human causal biology and closed-loop chemistry platform to generate and optimize new PD drug candidates.
Aspen Neuroscience closed a $115M Series C to accelerate its autologous iPSC-derived Parkinson’s therapy ANPD001, scale manufacturing, and prepare for commercial-stage readiness.
ReviR Therapeutics secured a $4.6M CIRM grant to advance its HTT–PMS1 genetic medicine program, designed to selectively reduce mutant huntingtin and modulate somatic CAG expansion in Huntington’s disease.
The ALS Association awarded $2M+ in grants across 107 U.S. ALS clinics, strengthening multidisciplinary care capacity as ALS prevalence climbs.
SciNeuro secured $5M from The Michael J. Fox Foundation to accelerate its LRRK2-targeted antisense oligonucleotide SNP614, which has shown potent knockdown and strong NHP safety as it advances toward IND.
Regulatory & Clinical Programs Advance With Precision
Paradromics received FDA IDE approval to launch its Connect-One early feasibility study, marking the first U.S. clinical trial of a high-bandwidth, fully implantable brain–computer interface designed to restore communication and digital control for patients with severe paralysis.
Discovery & Translational Neuroscience Show Strong Momentum
Gain Therapeutics presented new preclinical data showing its GCase modulator GT-02287 reduces mitochondrial stress, improves neuronal health, restores complex I activity, and normalizes MIRO1 in Parkinson’s disease models, strengthening its disease-modifying rationale.
ATED Therapeutics won the Fierce Life Sciences Innovation Award for its tRF-based rapid Parkinson’s blood test, offering sub-2-hour molecular diagnostics for pre-symptomatic detection and monitoring. The qPCR platform supports scalable screening across clinical settings.
Neurotechnology & Imaging Accelerate Through Partnerships & Innovation
Bracco Imaging secured ANVISA approval for AiMIFY™, its AI-powered MRI contrast enhancement platform developed with Subtle Medical. The software amplifies gadolinium contrast for detecting subtle brain lesions and expands access across Latin America following prior FDA and CE Mark clearances.
A landmark bench study demonstrated that inTRAvent Medical’s SOLOPASS 2.0, the first FDA-cleared ultrasound-guided ventricular catheter navigation system, delivers dramatically higher placement accuracy and reduced deviation, reinforcing its potential to reduce shunt failure rates in hydrocephalus surgery.
For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com.
